. 2012 Jun 16;32(5):507–517. doi: 10.1007/s10792-012-9589-2

Table 3.

Studies demonstrating the efficacy and safety of difluprednate for postoperative inflammation

Study parameters	Korenfeld et al. [8]	Smith et al. [44]
Comparator	Placebo	Placebo
No. of patients	438	124
Treatment duration	15 days^a	16 day treatment period^a
Patients with a clinical response^b (%)	Difluprednate BID—72.7^c	Difluprednate—74.7 %
Patients with a clinical response^b (%)	Difluprednate QID—71^c	Placebo—42.5
Mean IOP at final visit	No significant changes from baseline for the difluprednate group reported	Not reported
Clinically significant increases in IOP (≥10 mmHg)	n = 3 for difluprednate BID;	n = 3 for difluprednate
	n = 3 for difluprednate QID;
	n = 2 for placebo

ACI anterior chamber inflammation, BID twice daily, QID 4 times daily, IOP intraocular pressure

^aThe treatment period was followed by a 2 week tapering period before treatment was stopped

^bClinical response defined as anterior chamber cell count <5 and flare Grade 0

^cPrior to commencement of dose-tapering